Fosun Apexvac

Fosun Apexvac, primarily operating as Fosun Antejin, is a specialized vaccine subsidiary of the global healthcare group Fosun Pharma. Based in China, the company focuses on the research, development, and large-scale manufacturing of high-quality human vaccines to address significant public health needs. Its lead product candidate is a 13-valent pneumococcal conjugate vaccine (PCV13), which has successfully completed Phase 3 clinical trials and is positioned to compete in the global respiratory infection market. In addition to its pneumococcal program, Fosun Apexvac is advancing a pipeline that includes rabies vaccines and various combination vaccines such as DTP-Hib. The company operates modern manufacturing facilities that adhere to international GMP standards, supporting Fosun Pharma's broader strategy to expand its footprint in the global vaccine industry. Through its integration with Fosun Pharma, the company leverages extensive R&D resources and commercialization networks to provide innovative immunization solutions.